Mechanisms of disease: Systemic lupus erythematosus

New England Journal of Medicine

Volumn 365, Issue 22, 2011, Pages 2110-2121

  Tsokos, George C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CD3 ANTIBODY; CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP BINDING PROTEIN; CYCLOPHOSPHAMIDE; DNA ANTIBODY; ECULIZUMAB; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SEX HORMONE; TACROLIMUS; TOCILIZUMAB; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; DISEASE PREDISPOSITION; DNA METHYLATION; DNA POLYMORPHISM; DRUG APPROVAL; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENE LOCUS; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TREATMENT INDICATION; ULTRAVIOLET RADIATION; X CHROMOSOME; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; KIDNEY; MALE; METABOLISM; PATHOLOGY; SEX DIFFERENCE; ULTRASTRUCTURE;

FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; RECEPTORS, ANTIGEN, T-CELL; SEX FACTORS; TRANSCRIPTION, GENETIC;

EID: 82555196095     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/nejmra1100359     Document Type: Review

References (100)

1. Duarte C, Couto M, Ines L, Liang MH. Epidemiology of systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon J, Koike T, eds. Systemic lupus erythematosus. 5th ed. London: Elsevier, 2011:673-96.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
3. Pons-Estel GJ, Alaræon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
4. Moser KL, Kelly JA, Lessard CJ, Harley JB. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009;10:373-9.
5. Tsokos GC, Kammer GM. Molecular aberrations in human systemic lupus erythematosus. Mol Med Today 2000;6:418-24.
6. Roozendaal R, Carroll MC. Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev 2007;219:157-66. (Pubitemid 47390008)
7. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004;22:431-56. (Pubitemid 38680429)
8. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998;10:690-6. (Pubitemid 28558585)
9. Gorman CL, Russell AI, Zhang Z, Cunninghame GD, Cope AP, Vyse TJ. Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematosus patients and healthy controls. J Immunol 2008;180:1060-70.
10. Tan W, Sunahori K, Zhao J, et al. Association of PPP2CA polymorphisms with SLE susceptibility in multiple ethnic groups. Arthritis Rheum 2011 May 16 (Epub ahead of print).
11. Gateva V, Sandling JK, Hom G et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1228-33.
12. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-53.
13. Blanchong CA, Chung EK, Rupert KL, et al. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol 2001;1:365-92. (Pubitemid 32197537)
14. Niederer HA, Clatworthy MR, Willcocks LC, Smith KG. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 2010;1183:69-88.
15. Kelley J, Johnson MR, Alarćon GS, Kimberly RP, Edberg JC. Variation in the relative copy number of the TLR7 gene in patients with systemic lupus erythematosus and healthy control subjects. Arthritis Rheum 2007;56:3375-8. (Pubitemid 47585432)
16. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006;176:7143-7. (Pubitemid 43849013)
17. Simard JF, Costenbader KH, Liang MH, Karlson EW, Mittleman MA. Exposure to maternal smoking and incident SLE in a prospective cohort study. Lupus 2009;18:431-5.
18. Tsokos GC, Magrath IT, Balow JE. Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 1983;131:1797-801. (Pubitemid 13006895)
19. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004;172:1287-94. (Pubitemid 38113792)
20. Poole BD, Scofield RH, Harley JB, James JA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 2006;39:63-70. (Pubitemid 43878521)
21. Smith-Bouvier DL, Divekar AA, Sasidhar M, et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008;205:1099-108. (Pubitemid 351679685)
22. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum 1993;36:1392-7. (Pubitemid 23304209)
23. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum 2002;47:202-9. (Pubitemid 34303848)
24. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2924-7.
25. Tenbrock K, Juang YT, Leukert N, Roth J, Tsokos GC. The transcriptional repressor cAMP response element modulator alpha interacts with histone deacetylase 1 to repress promoter activity. J Immunol 2006;177:6159-64. (Pubitemid 44628833)
26. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003;111:539-52. (Pubitemid 36228011)
27. Crispín JC, Liossis SN, Kis-Toth K, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010;16:47-57.
28. Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupusprone mice by promoting lipid raft aggregation. J Immunol 2008;181:4019-26.
29. Juang YT, Wang Y, Solomou EE, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005;115:996-1005. (Pubitemid 40489404)
30. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 2005;115:3193-204. (Pubitemid 41567584)
31. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009;27:485-517.
32. Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008;181:8761-6.
33. Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol 2009;183:3160-9.
34. Li Y, Harada T, Juang YT, et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007;178:1938-47. (Pubitemid 46154667)
35. Estess P, DeGrendele HC, Pascual V, Siegelman MH. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest 1998;102:1173-82. (Pubitemid 28436277)
36. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000;165:5970-9.
37. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999;189:1639-48.
38. Yurasov S, Tiller T, Tsuiji M, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006;203:2255-61. (Pubitemid 44498360)
39. Jacobi AM, Zhang J, Mackay M, Aranow C, Diamond B. Phenotypic characterization of autoreactive B cells - checkpoints of B cell tolerance in patients with systemic lupus erythematosus. PLoS ONE 2009;4(6):e5776.
40. Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-57. (Pubitemid 26415075)
41. Mackay M, Stanevsky A, Wang T, et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J Exp Med 2006;203:2157-64. (Pubitemid 44352236)
42. Surolia I, Pirnie SP, Chellappa V, et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 2010;466:243-7.
43. Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005;37:1317-9. (Pubitemid 41722185)
44. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41:1828-34. (Pubitemid 28465537)
45. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3. (Pubitemid 33063928)
46. Decker P, Singh-Jasuja H, Haager S, Kotter I, Rammensee HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J Immunol 2005;174:3326-34. (Pubitemid 40354036)
47. Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005;115:407-17. (Pubitemid 40385482)
48. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
49. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2951-62. (Pubitemid 44497776)
50. Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007;316:359-86.
51. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43. (Pubitemid 33704208)
52. Kimberly RP. Immune complexes in the rheumatic diseases. Rheum Dis Clin North Am 1987;13:583-96.
53. Li X, Ptacek TS, Brown EE, Edberg JC. Fcgamma receptors: structure, function and role as genetic risk factors in SLE. Genes Immun 2009;10:380-9.
54. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-9. (Pubitemid 351397089)
55. Shivakumar S, Tsokos GC, Datta SK. T cell receptor alpha/beta expressing double- negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989;143:103-12. (Pubitemid 19174206)
56. Leijh PC, van den Barselaar MT, van Zwet TL, Daha MR, van Furth R. Requirement of extracellular complement and immunoglobulin for intracellular killing of micro-organisms by human monocytes. J Clin Invest 1979;63:772-84. (Pubitemid 9167047)
57. Manson JJ, Ma A, Rogers P, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther 2009;11:R154.
58. Hedberg A, Mortensen ES, Rekvig OP. Chromatin as a target antigen in human and murine lupus nephritis. Arthritis Res Ther 2011;13:214.
59. Brucato A, Cimaz R, Caporali R, Ramoni V, Buyon J. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011;40:27-41.
60. Kowal C, Degiorgio LA, Lee JY, et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 2006; 103:19854-9. (Pubitemid 46037520)
61. Lee JY, Huerta PT, Zhang J, et al. Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus. Nat Med 2009;15:91-6.
62. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498-509.
63. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004;10:1222-6. (Pubitemid 39540439)
64. Tsokos GC, Fleming SD. Autoimmunity, complement activation, tissue injury and reciprocal effects. Curr Dir Autoimmun 2004;7:149-64.
65. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011;186:1849-60.
66. Renaudineau Y, Deocharan B, Jousse S, Renaudineau E, Putterman C, Youinou P. Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmun Rev 2007;6:464-8. (Pubitemid 47069972)
67. Liu K, Li QZ, Delgado-Vega AM, et al. Kallikrein genes are associated with lupus and glomerular basement membranespecific antibody-induced nephritis in mice and humans. J Clin Invest 2009;119:911-23.
68. Cohen PL, Caricchio R. Genetic models for the clearance of apoptotic cells. Rheum Dis Clin North Am 2004;30:473-86. (Pubitemid 38916997)
69. Deng GM, Liu L, Kyttaris VC, Tsokos GC. Lupus serum IgG induces skin inflammation through the TNFR1 signaling pathway. J Immunol 2010;184:7154-61.
70. Urowitz MB, Gladman D, Ibanez D, et al. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:881-7.
71. Urowitz MB, Gladman D, Ibanez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007;16:731-5. (Pubitemid 47517869)
72. Valdivielso P, Gómez-Doblas JJ, Macias M, et al. Lupus-associated endothelial dysfunction, disease activity and arteriosclerosis. Clin Exp Rheumatol 2008;26:827-33.
73. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 2009;120:2012-24.
74. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677-83. (Pubitemid 38596281)
75. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23. (Pubitemid 36350866)
76. Juang YT, Peoples C, Kafri R, et al. A systemic lupus erythematosus gene expression array in disease diagnosis and classification: a preliminary report. Lupus 2011;20:243-9.
77. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004;10:411-5. (Pubitemid 38508521)
78. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 2007;6:223-35.
79. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57. (Pubitemid 32799338)
80. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010;77:152-60.
81. Contreras G, Pardo V, LeClercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80. (Pubitemid 38269274)
82. Boumpas DT, Bertsias GK, Balow JE. A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? Ann Rheum Dis 2010;69:2059-61.
83. Davidson A. Targeting BAFF in auto-immunity. Curr Opin Immunol 2010;22:732-9.
84. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999;285:260-3. (Pubitemid 29330000)
85. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31.
86. Kishimoto T, Hirano T. Molecular regulation of B lymphocyte response. Annu Rev Immunol 1988;6:485-512. (Pubitemid 19141593)
87. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000;85:207-14.
88. Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev 2008;22:65-74. (Pubitemid 351282444)
89. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9. (Pubitemid 39062719)
90. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009;18:767-76.
91. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
92. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33.
93. Alaræon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54. (Pubitemid 36278013)
94. Hahn BH, Ebling F, Singh RR, Singh RP, Karpouzas G, La Cava A. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 2005;1051:433-41. (Pubitemid 41362773)
95. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077-87.
96. Su K, Yang H, Li X, et al. Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus. J Immunol 2007;178:3272-80. (Pubitemid 46333211)
97. Ichinose K, Juang YT, Crispin JC, Kis-Toth K, Tsokos GC. Suppression of autoimmunity and organ pathology in lupusprone mice upon inhibition of calcium/ calmodulin-dependent protein kinase type IV. Arthritis Rheum 2011;63:523-9.
98. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010;62:2086-92.
99. Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum 2011;63:2058-66.
100. Fernandez DR, Telarico T, Bonilla E, et al. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009;182:2063-73.